Article
Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
Breast cancer research and treatment - 1 Apr 2014
Fontein Duveken B Y, Houtsma Daniel, Nortier Johan W R, Baak-Pablo Renee F, Kranenbarg Elma Meershoek-Klein, van der Straaten Tahar R J H M, Putter Hein, Seynaeve Caroline, Gelderblom Hans, van de Velde Cornelis J H, Guchelaar Henk-Jan
Abstract excerpt
Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) are known side-effects of aromatase inhibitors, and may be related to genetic variations of the aromatase gene (CYP19A1). We investigated the relationship between these specific AEs and single nucleotide polymorphisms (SNPs) in the CYP19A1 gene in postmenopausal, hormone receptor-positive early breast cancer (BC) patients treated with adjuvant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.